drugset / Trial / NCT00389831

Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms

NCT00389831

Phase 2 Completed 44 enrolled UCB Pharma
RandomizedParallel-groupDouble-blindTreatment

Summary

The main objective of this phase 2a proof-of-concept trial is to assess the efficacy of rotigotine nasal spray in ascending doses in subjects with idiopathic Restless Legs Syndrome.

Timeline

Start
2006-08
Primary completion
2006-11
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 62 ug Intranasal
Subject Rotigotine Unknown 124 ug Intranasal
Subject Rotigotine Unknown 247 ug Intranasal